Improving biophysical properties of a bispecific antibody scaffold to aid developability

References

• Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182 - 97; http://dx.doi.org/10.4161/mabs.4.2.19000; PMID: 22453100
   PubMed Web of Science ®Google Scholar
• Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317:1261 - 9; http://dx.doi.org/10.1016/j.yexcr.2011.02.013; PMID: 21371474
   PubMed Web of Science ®Google Scholar
• Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods 2001; 248:1 - 6; http://dx.doi.org/10.1016/S0022-1759(00)00338-0; PMID: 11223064
   PubMed Web of Science ®Google Scholar
• Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7 - 15; http://dx.doi.org/10.1016/S0022-1759(00)00339-2; PMID: 11223065
   PubMed Web of Science ®Google Scholar
• Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20:493 - 9; http://dx.doi.org/10.1016/j.coi.2008.05.013; PMID: 18586093
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617 - 21; http://dx.doi.org/10.1093/protein/9.7.617; PMID: 8844834
   PubMedGoogle Scholar
• Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26 - 35; http://dx.doi.org/10.1006/jmbi.1997.1116; PMID: 9231898
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677 - 81; http://dx.doi.org/10.1038/nbt0798-677; PMID: 9661204
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18:1570 - 4; http://dx.doi.org/10.1038/nm.2942; PMID: 23023498
   PubMed Web of Science ®Google Scholar
• Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; http://dx.doi.org/10.1126/scitranslmed.3002230; PMID: 21613623
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187 - 92; http://dx.doi.org/10.1073/pnas.1019002108; PMID: 21690412
   PubMed Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653 - 63; http://dx.doi.org/10.4161/mabs.21379; PMID: 22925968
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960; PMID: 18519697
   PubMed Web of Science ®Google Scholar
• Klein C, Schaefer W. Bivalent, bispecific antibodies. USPTO. US2009/023811A1, 2009:para 268.
   Google Scholar
• Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850 - 9; http://dx.doi.org/10.1074/jbc.M110.113910; PMID: 20444694
   PubMed Web of Science ®Google Scholar
• Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem 2012; 287:43331 - 9; http://dx.doi.org/10.1074/jbc.M112.397869; PMID: 23118228
   PubMed Web of Science ®Google Scholar
• Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204 - 19; http://dx.doi.org/10.1016/j.jmb.2012.04.020; PMID: 22543237
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145 - 50; http://dx.doi.org/10.1073/pnas.1220145110; PMID: 23479652
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637 - 46; http://dx.doi.org/10.1074/jbc.M110.117382; PMID: 20400508
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195 - 202; http://dx.doi.org/10.1093/protein/gzp094; PMID: 20299542
   PubMed Web of Science ®Google Scholar
• Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546 - 57; http://dx.doi.org/10.4161/mabs.3.6.18123; PMID: 22123055
   PubMed Web of Science ®Google Scholar
• Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289:1 - 30; http://dx.doi.org/10.1016/j.ijpharm.2004.11.014; PMID: 15652195
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675 - 87; PMID: 18729019
   PubMed Web of Science ®Google Scholar
• Wen J, Jiang Y, Hymes K, Gong K, Nahri L. Using Differential Scanning Calorimetry in Understanding the Correlation Between Thermal Stability and Protein Stability: A Case Study. Microcal Application Note, 2011.
   Google Scholar
• Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 2012; 4:17 - 23; http://dx.doi.org/10.4161/mabs.4.1.18347; PMID: 22327427
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar B, Mengisen S, Antochshuk V, et al. Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 2013; 5; http://dx.doi.org/10.4161/mabs.25269
   Web of Science ®Google Scholar
• Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs 2013; 5:255 - 62; http://dx.doi.org/10.4161/mabs.23392; PMID: 23412563
   PubMed Web of Science ®Google Scholar
• Bolon DN, Grant RA, Baker TA, Sauer RT. Specificity versus stability in computational protein design. Proc Natl Acad Sci U S A 2005; 102:12724 - 9; http://dx.doi.org/10.1073/pnas.0506124102; PMID: 16129838
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20:2361 - 70; http://dx.doi.org/10.1021/bi00512a001; PMID: 7236608
   PubMed Web of Science ®Google Scholar
• Dall’Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266 - 73; http://dx.doi.org/10.1021/bi980270i; PMID: 9649307
   PubMed Web of Science ®Google Scholar
• Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006; 65:712 - 25; http://dx.doi.org/10.1002/prot.21123; PMID: 16981200
   PubMed Web of Science ®Google Scholar
• Jayaram B, Sprous D, Beveridge DL. Solvation Free Energy of Biomacromolecules: Parameters for a Modified Generalized Born Model Consistent with the AMBER Force Field. J Phys Chem B 1998; 102:9571 - 6; http://dx.doi.org/10.1021/jp982007x
   Web of Science ®Google Scholar
• Vajda S, Sippl M, Novotny J. Empirical potentials and functions for protein folding and binding. Curr Opin Struct Biol 1997; 7:222 - 8; http://dx.doi.org/10.1016/S0959-440X(97)80029-2; PMID: 9094333
   PubMed Web of Science ®Google Scholar
• Xiang Z, Honig B. Extending the accuracy limits of prediction for side-chain conformations. J Mol Biol 2001; 311:421 - 30; http://dx.doi.org/10.1006/jmbi.2001.4865; PMID: 11478870
   PubMed Web of Science ®Google Scholar
• Davis IW, Arendall WB 3rd, Richardson DC, Richardson JS. The backrub motion: how protein backbone shrugs when a sidechain dances. Structure 2006; 14:265 - 74; http://dx.doi.org/10.1016/j.str.2005.10.007; PMID: 16472746
   PubMed Web of Science ®Google Scholar
• De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189 - 201; http://dx.doi.org/10.1016/j.clim.2009.01.009; PMID: 19269256
   PubMed Web of Science ®Google Scholar
• Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 2010; 24:1 - 8; http://dx.doi.org/10.2165/11318560-000000000-00000; PMID: 20055528
   PubMed Web of Science ®Google Scholar
• Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008; 97:1414 - 26; http://dx.doi.org/10.1002/jps.21104; PMID: 17721938
   PubMed Web of Science ®Google Scholar
• Li CH, Narhi LO, Wen J, Dimitrova M, Wen ZQ, Li J, et al. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc. Biochemistry 2012; 51:10056 - 65; http://dx.doi.org/10.1021/bi300702e; PMID: 23078371
   PubMed Web of Science ®Google Scholar
• Demarest SJ, Rogers J, Hansen G. Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences. J Mol Biol 2004; 335:41 - 8; http://dx.doi.org/10.1016/j.jmb.2003.10.040; PMID: 14659738
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355:751 - 7; http://dx.doi.org/10.1016/j.bbrc.2007.02.042; PMID: 17321501
   PubMed Web of Science ®Google Scholar
• Feige MJ, Walter S, Buchner J. Folding mechanism of the CH2 antibody domain. J Mol Biol 2004; 344:107 - 18; http://dx.doi.org/10.1016/j.jmb.2004.09.033; PMID: 15504405
   PubMed Web of Science ®Google Scholar
• Thies MJ, Mayer J, Augustine JG, Frederick CA, Lilie H, Buchner J. Folding and association of the antibody domain CH3: prolyl isomerization preceeds dimerization. J Mol Biol 1999; 293:67 - 79; http://dx.doi.org/10.1006/jmbi.1999.3128; PMID: 10512716
   PubMed Web of Science ®Google Scholar
• Thies MJ, Talamo F, Mayer M, Bell S, Ruoppolo M, Marino G, et al. Folding and oxidation of the antibody domain C(H)3. J Mol Biol 2002; 319:1267 - 77; http://dx.doi.org/10.1016/S0022-2836(02)00375-3; PMID: 12079363
   PubMed Web of Science ®Google Scholar
• McAuley A, Jacob J, Kolvenbach CG, Westland K, Lee HJ, Brych SR, et al. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci 2008; 17:95 - 106; http://dx.doi.org/10.1110/ps.073134408; PMID: 18156469
   PubMed Web of Science ®Google Scholar
• Reichert JM. Bispecific antibodies and ADCs: Once and future kings?. MAbs 2011; 3:329 - 30; http://dx.doi.org/10.4161/mabs.3.4.16589; PMID: 21654205
   PubMed Web of Science ®Google Scholar
• Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem 2010; 21:1588 - 95; http://dx.doi.org/10.1021/bc900434c; PMID: 20698491
   PubMed Web of Science ®Google Scholar
• Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci 2012; 101:895 - 913; http://dx.doi.org/10.1002/jps.22812; PMID: 22083792
   PubMed Web of Science ®Google Scholar
• Raibekas AA. Estimation of protein aggregation propensity with a melting point apparatus. Anal Biochem 2008; 380:331 - 2; http://dx.doi.org/10.1016/j.ab.2008.05.023; PMID: 18544334
   PubMed Web of Science ®Google Scholar
• Woods RJ, Xie M, von Kreudenstein T, Ng G, Dixit SB. LC-MS characterization and purity assessment of a prototype bispecific antibody. MAbs 2013; 5; http://dx.doi.org/10.4161/mabs.25488
   Web of Science ®Google Scholar
• Girod PA, Le Fourn V. Rapid production of functional proteins of a combinatorial IgG library in CHO cells. Bioprocess Int 2012; 10:58 - 61
   Google Scholar
• Serpieri F, Inocencio A, de Oliveira JM, Pimenta AA Jr., Garbuio A, Kalil J, et al. Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells. Mol Biotechnol 2010; 45:218 - 25; http://dx.doi.org/10.1007/s12033-010-9269-2; PMID: 20336495
   PubMed Web of Science ®Google Scholar